File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

TitleImpact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
Authors
Issue Date2010
PublisherOxford University Press. The Journal's web site is located at http://jncicancerspectrum.oxfordjournals.org/
Citation
Journal Of The National Cancer Institute, 2010, v. 102 n. 5, p. 325-339 How to Cite?
AbstractBackground The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women in that they were "negative to 14 HPV types" and in a mixed population of HPV-exposed and-unexposed women (intention-to-treat group).MethodsThis analysis studied 17 622 women aged 15-26 years who were enrolled in one of two randomized, placebo-controlled, efficacy trials for the HPV6/11/16/18 vaccine (first patient on December 28, 2001, and studies completed July 31, 2007). Vaccine or placebo was given at day 1, month 2, and month 6. All women underwent cervicovaginal sampling and Papanicolaou (Pap) testing at day 1 and every 6-12 months thereafter. Outcomes were any cervical intraepithelial neoplasia; any external anogenital and vaginal lesions; Pap test abnormalities; and procedures such as colposcopy and definitive therapy. Absolute rates are expressed as women with endpoint per 100 person-years at risk.ResultsThe average follow-up was 3.6 years (maximum of 4.9 years). In the population that was negative to 14 HPV types, vaccination was up to 100% effective in reducing the risk of HPV16/18-related high-grade cervical, vulvar, and vaginal lesions and of HPV6/11-related genital warts. In the intention-to-treat group, vaccination also statistically significantly reduced the risk of any high-grade cervical lesions (19.0% reduction; rate vaccine = 1.43, rate placebo = 1.76, difference = 0.33, 95% confidence interval [CI] = 0.13 to 0.54), vulvar and vaginal lesions (50.7% reduction; rate vaccine = 0.10, rate placebo = 0.20, difference = 0.10, 95% CI = 0.04 to 0.16), genital warts (62.0% reduction; rate vaccine = 0.44, rate placebo = 1.17, difference = 0.72, 95% CI = 0.58 to 0.87), Pap abnormalities (11.3% reduction; rate vaccine = 10.36, rate placebo = 11.68, difference = 1.32, 95% CI = 0.74 to 1.90), and cervical definitive therapy (23.0% reduction; rate vaccine = 1.97, rate placebo = 2.56, difference = 0.59, 95% CI = 0.35 to 0.83), irrespective of causal HPV type.ConclusionsHigh-coverage HPV vaccination programs among adolescents and young women may result in a rapid reduction of genital warts, cervical cytological abnormalities, and diagnostic and therapeutic procedures. In the longer term, substantial reductions in the rates of cervical, vulvar, and vaginal cancers may follow.
Persistent Identifierhttp://hdl.handle.net/10722/87275
ISSN
2023 Impact Factor: 9.9
2023 SCImago Journal Rankings: 4.986
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMunoz, Nen_HK
dc.contributor.authorKjaer, SKen_HK
dc.contributor.authorSigurdsson, Ken_HK
dc.contributor.authorIversen, OEen_HK
dc.contributor.authorHernandezAvila, Men_HK
dc.contributor.authorWheeler, CMen_HK
dc.contributor.authorPerez, Gen_HK
dc.contributor.authorBrown, DRen_HK
dc.contributor.authorKoutsky, LAen_HK
dc.contributor.authorTay, EHen_HK
dc.contributor.authorGarcia, PJen_HK
dc.contributor.authorAult, KAen_HK
dc.contributor.authorGarland, SMen_HK
dc.contributor.authorLeodolter, Sen_HK
dc.contributor.authorOlsson, SEen_HK
dc.contributor.authorTang, GWKen_HK
dc.contributor.authorFerris, DGen_HK
dc.contributor.authorPaavonen, Jen_HK
dc.contributor.authorSteben, Men_HK
dc.contributor.authorBosch, FXen_HK
dc.contributor.authorDillner, Jen_HK
dc.contributor.authorHuh, WKen_HK
dc.contributor.authorJoura, EAen_HK
dc.contributor.authorKurman, RJen_HK
dc.contributor.authorMajewski, Sen_HK
dc.contributor.authorMyers, ERen_HK
dc.contributor.authorVilla, LLen_HK
dc.contributor.authorTaddeo, FJen_HK
dc.contributor.authorRoberts, Cen_HK
dc.contributor.authorTadesse, Aen_HK
dc.contributor.authorBryan, JTen_HK
dc.contributor.authorLupinacci, LCen_HK
dc.contributor.authorGiacoletti, KEDen_HK
dc.contributor.authorSings, HLen_HK
dc.contributor.authorJames, MKen_HK
dc.contributor.authorHesley, TMen_HK
dc.contributor.authorBarr, Een_HK
dc.contributor.authorHaupt, RMen_HK
dc.date.accessioned2010-09-06T09:27:35Z-
dc.date.available2010-09-06T09:27:35Z-
dc.date.issued2010en_HK
dc.identifier.citationJournal Of The National Cancer Institute, 2010, v. 102 n. 5, p. 325-339en_HK
dc.identifier.issn0027-8874en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87275-
dc.description.abstractBackground The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women in that they were "negative to 14 HPV types" and in a mixed population of HPV-exposed and-unexposed women (intention-to-treat group).MethodsThis analysis studied 17 622 women aged 15-26 years who were enrolled in one of two randomized, placebo-controlled, efficacy trials for the HPV6/11/16/18 vaccine (first patient on December 28, 2001, and studies completed July 31, 2007). Vaccine or placebo was given at day 1, month 2, and month 6. All women underwent cervicovaginal sampling and Papanicolaou (Pap) testing at day 1 and every 6-12 months thereafter. Outcomes were any cervical intraepithelial neoplasia; any external anogenital and vaginal lesions; Pap test abnormalities; and procedures such as colposcopy and definitive therapy. Absolute rates are expressed as women with endpoint per 100 person-years at risk.ResultsThe average follow-up was 3.6 years (maximum of 4.9 years). In the population that was negative to 14 HPV types, vaccination was up to 100% effective in reducing the risk of HPV16/18-related high-grade cervical, vulvar, and vaginal lesions and of HPV6/11-related genital warts. In the intention-to-treat group, vaccination also statistically significantly reduced the risk of any high-grade cervical lesions (19.0% reduction; rate vaccine = 1.43, rate placebo = 1.76, difference = 0.33, 95% confidence interval [CI] = 0.13 to 0.54), vulvar and vaginal lesions (50.7% reduction; rate vaccine = 0.10, rate placebo = 0.20, difference = 0.10, 95% CI = 0.04 to 0.16), genital warts (62.0% reduction; rate vaccine = 0.44, rate placebo = 1.17, difference = 0.72, 95% CI = 0.58 to 0.87), Pap abnormalities (11.3% reduction; rate vaccine = 10.36, rate placebo = 11.68, difference = 1.32, 95% CI = 0.74 to 1.90), and cervical definitive therapy (23.0% reduction; rate vaccine = 1.97, rate placebo = 2.56, difference = 0.59, 95% CI = 0.35 to 0.83), irrespective of causal HPV type.ConclusionsHigh-coverage HPV vaccination programs among adolescents and young women may result in a rapid reduction of genital warts, cervical cytological abnormalities, and diagnostic and therapeutic procedures. In the longer term, substantial reductions in the rates of cervical, vulvar, and vaginal cancers may follow.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://jncicancerspectrum.oxfordjournals.org/en_HK
dc.relation.ispartofJournal of the National Cancer Instituteen_HK
dc.rightsJournal of the National Cancer Institute (Print). Copyright © Oxford University Press.en_HK
dc.titleImpact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Womenen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0027-8874&volume=102&spage=1&epage=15&date=2010&atitle=Impact+of+Human+Papillomavirus+(HPV)-6/11/16/18+Vaccine+on+All+HPV-Associated+Genital+Diseases+in+Young+Womenen_HK
dc.identifier.emailTang, GWK:gwktang@hkucc.hku.hken_HK
dc.identifier.authorityTang, GWK=rp00328en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1093/jnci/djp534en_HK
dc.identifier.pmid20139221-
dc.identifier.scopuseid_2-s2.0-77749279739en_HK
dc.identifier.hkuros169005en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77749279739&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume102en_HK
dc.identifier.issue5en_HK
dc.identifier.spage325en_HK
dc.identifier.epage339en_HK
dc.identifier.isiWOS:000275254600010-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridMunoz, N=7102360543en_HK
dc.identifier.scopusauthoridKjaer, SK=7004418213en_HK
dc.identifier.scopusauthoridSigurdsson, K=35475355400en_HK
dc.identifier.scopusauthoridIversen, OE=7102966661en_HK
dc.identifier.scopusauthoridHernandezAvila, M=7005968193en_HK
dc.identifier.scopusauthoridWheeler, CM=7202505711en_HK
dc.identifier.scopusauthoridPerez, G=16307983600en_HK
dc.identifier.scopusauthoridBrown, DR=7407095050en_HK
dc.identifier.scopusauthoridKoutsky, LA=7006120337en_HK
dc.identifier.scopusauthoridTay, EH=7004902850en_HK
dc.identifier.scopusauthoridGarcia, PJ=7201693727en_HK
dc.identifier.scopusauthoridAult, KA=7005241226en_HK
dc.identifier.scopusauthoridGarland, SM=7102220459en_HK
dc.identifier.scopusauthoridLeodolter, S=7005056838en_HK
dc.identifier.scopusauthoridOlsson, SE=7202623557en_HK
dc.identifier.scopusauthoridTang, GWK=7401633864en_HK
dc.identifier.scopusauthoridFerris, DG=17634377600en_HK
dc.identifier.scopusauthoridPaavonen, J=7102724434en_HK
dc.identifier.scopusauthoridSteben, M=6602790643en_HK
dc.identifier.scopusauthoridBosch, FX=7201833375en_HK
dc.identifier.scopusauthoridDillner, J=7007135194en_HK
dc.identifier.scopusauthoridHuh, WK=7006890930en_HK
dc.identifier.scopusauthoridJoura, EA=7004817276en_HK
dc.identifier.scopusauthoridKurman, RJ=7101640655en_HK
dc.identifier.scopusauthoridMajewski, S=7103224726en_HK
dc.identifier.scopusauthoridMyers, ER=35433205900en_HK
dc.identifier.scopusauthoridVilla, LL=7102824355en_HK
dc.identifier.scopusauthoridTaddeo, FJ=6603004214en_HK
dc.identifier.scopusauthoridRoberts, C=35474924800en_HK
dc.identifier.scopusauthoridTadesse, A=6602812727en_HK
dc.identifier.scopusauthoridBryan, JT=7202481712en_HK
dc.identifier.scopusauthoridLupinacci, LC=16307166200en_HK
dc.identifier.scopusauthoridGiacoletti, KED=15131768700en_HK
dc.identifier.scopusauthoridSings, HL=8401383500en_HK
dc.identifier.scopusauthoridJames, MK=10438802400en_HK
dc.identifier.scopusauthoridHesley, TM=6603486789en_HK
dc.identifier.scopusauthoridBarr, E=7005643832en_HK
dc.identifier.scopusauthoridHaupt, RM=11940557600en_HK
dc.identifier.citeulike6649590-
dc.identifier.issnl0027-8874-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats